Ionis Pharmaceuticals (IONS) Set to Announce Quarterly Earnings on Tuesday

Ionis Pharmaceuticals (NASDAQ:IONS) is set to issue its quarterly earnings data before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of ($1.07) per share for the quarter. Ionis Pharmaceuticals has set its FY 2024 guidance at EPS.Parties interested in registering for the company’s conference call can do so using this link.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings data on Wednesday, February 21st. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.72. The company had revenue of $325.00 million during the quarter, compared to analyst estimates of $176.01 million. Ionis Pharmaceuticals had a negative return on equity of 90.29% and a negative net margin of 46.32%. The firm’s revenue for the quarter was up 113.8% on a year-over-year basis. During the same quarter last year, the company earned ($0.37) EPS. On average, analysts expect Ionis Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Ionis Pharmaceuticals Stock Down 2.6 %

Ionis Pharmaceuticals stock opened at $41.97 on Friday. The firm has a market cap of $6.12 billion, a price-to-earnings ratio of -16.39 and a beta of 0.41. The stock has a fifty day simple moving average of $43.07 and a two-hundred day simple moving average of $46.98. Ionis Pharmaceuticals has a 12 month low of $34.32 and a 12 month high of $54.44. The company has a current ratio of 5.90, a quick ratio of 5.83 and a debt-to-equity ratio of 3.18.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. JPMorgan Chase & Co. lifted their target price on Ionis Pharmaceuticals from $52.00 to $55.00 and gave the stock a “neutral” rating in a report on Thursday, February 1st. Oppenheimer lifted their target price on Ionis Pharmaceuticals from $72.00 to $75.00 and gave the stock an “outperform” rating in a report on Tuesday, April 9th. Piper Sandler lifted their target price on Ionis Pharmaceuticals from $62.00 to $63.00 and gave the stock an “overweight” rating in a report on Thursday, February 22nd. Royal Bank of Canada lifted their target price on Ionis Pharmaceuticals from $65.00 to $70.00 and gave the stock an “outperform” rating in a report on Friday, January 26th. Finally, William Blair reissued an “outperform” rating on shares of Ionis Pharmaceuticals in a report on Tuesday, April 9th. One analyst has rated the stock with a sell rating, four have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Ionis Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $57.67.

Insider Buying and Selling

In other Ionis Pharmaceuticals news, EVP Joseph Baroldi sold 4,006 shares of the business’s stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $41.60, for a total value of $166,649.60. Following the sale, the executive vice president now owns 19,631 shares in the company, valued at approximately $816,649.60. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 2.65% of the stock is owned by company insiders.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.